Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN®): review of development and future perspectives
Open Access
- 6 December 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Surgery Today
- Vol. 42 (1), 8-28
- https://doi.org/10.1007/s00595-011-0075-7
Abstract
The mechanism of action of protein-bound polysaccharide K (PSK; KRESTIN®) involves the following actions: (1) recovery from immunosuppression induced by humoral factors such as transforming growth factor (TGF)-β or as a result of surgery and chemotherapy; (2) activation of antitumor immune responses including maturation of dendritic cells, correction of Th1/Th2 imbalance, and promotion of interleukin-15 production by monocytes; and (3) enhancement of the antitumor effect of chemotherapy by induction of apoptosis and inhibition of metastasis through direct actions on tumor cells. The clinical effectiveness of PSK has been demonstrated for various cancers. In patients with gastric or colorectal cancer, combined use of PSK with postoperative adjuvant chemotherapy prolongs survival, and this effect has been confirmed in multiple meta-analyses. For small-cell lung carcinoma, PSK in conjunction with chemotherapy prolongs the remission period. In addition, PSK has been shown to be effective against various other cancers, reduce the adverse effects of chemotherapy, and improve quality of life. Future studies should examine the effects of PSK under different host immune conditions and tumor properties, elucidate the mechanism of action exhibited in each situation, and identify biomarkers.Keywords
This publication has 93 references indexed in Scilit:
- Protein-bound polysaccharide-K reduces colitic tumors and improves survival of inflammatory bowel disease in vivoOncology Letters, 2011
- Recent concepts of antiangiogenic therapySurgery Today, 2010
- Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer)Surgery Today, 2010
- Recent advances in chemotherapy for advanced gastric cancer in JapanSurgery Today, 2010
- PSK may suppress CD57+ T cells to improve survival of advanced gastric cancer patientsInternational Journal of Clinical Oncology, 2010
- Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2009
- Perioperative host-tumor inflammatory interactions: A potential trigger for disease recurrence following a curative resection for colorectal cancerSurgery Today, 2008
- The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosisBMC Cancer, 2008
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- Complex networks orchestrate epithelial–mesenchymal transitionsNature Reviews Molecular Cell Biology, 2006